title: Tobramycin dosing in cystic fibrosis.
authors.forename: Alan
authors.initials: A
authors.lastname: Smyth
authors.forename: Daan
authors.initials: D
authors.lastname: Touw
authors.forename: Kelvin H-V
authors.initials: KH
authors.lastname: Tan
authors.forename: Carol
authors.initials: C
authors.lastname: Bertenshaw
authors.forename: David
authors.initials: D
authors.lastname: Stableforth
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications / Q000382:microbiology* / Q000503:physiopathology; D004334:Drug Administration Schedule; D006801:Humans; D007668:Kidney / Q000187:drug effects; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D014031:Tobramycin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000900:Anti-Bacterial Agents; D014031:Tobramycin